Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112835 | 0.90 | NR1I2 (0.57) | NR1I2 | |
| SCHEMBL17029014 | 0.87 | NR1I2 (0.58) | NR1I2 | |
| SCHEMBL17039307 | 0.87 | NR1I2 (0.58) | NR1I2 | |
| SCHEMBL17029023 | 0.83 | NR1I2 (0.58) | NR1I2 | |
| SCHEMBL18560613 | 0.83 | NR1I2 (0.44) | NR1I2 | |
| SCHEMBL470356 | 0.82 | NR1I2 (0.89) | NR1I2CYP3A4 | |
| SCHEMBL12079386 | 0.82 | NR1I2 (0.89) | NR1I2CYP3A4 | |
| SCHEMBL16112574 | 0.80 | NR1I2 (0.49) | NR1I2 | |
| SCHEMBL16113573 | 0.80 | NR1I2 (0.59) | NR1I2CYP3A4 | |
| SCHEMBL16113621 | 0.80 | NR1I2 (0.59) | NR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970274-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | claimed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | claimed |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-28 | — | — | US | claimed |
| EP-2970274-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014159959-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | claimed |
| EP-2970274-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-2970274-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| WO-2014159959-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | NR1I2 3265/4885CYP3A4 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.